Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Media Coverage
Our commercial intelligence and analysis are used by the Financial Times, the Wall Street Journal, Forbes, Nature, and Reuters, among others.
Take a look at the latest Evaluate and Vantage coverage. To learn more about how we work with healthcare and business reporters worldwide, or if you are looking for specific data and expert insights to support a current story, please contact us.
Latest Media Coverage
Nature Reviews Drug Discovery
FDA new drug approvals in Q1 2020
In a quarter that was marked by the rapid spread of the COVID-19 pandemic, drug approvals continued (Table 1), but launching was a completely different…
New York Times
Pharmaceutical Profits and Public Health Are Not Incompatible
The rapid spread of the coronavirus has revived a decades-old debate over pharmaceutical policy, with both sides doubling down on long-held views.
Nature Reviews Drug Discovery
Top companies and drugs by sales in 2019
Roche is back on top. Over the past few years, the tussle for biopharma’s biggest company by sales has largely been contested by Novartis and Pfizer; but a winning streak…
Browse the archive
The Pharma Letter
Report suggests industry overcoming patent cliff challenge
Projections from EvaluatePharma are quoted by the study, showing that the sector will experience compound annual growth of 6.9% for global prescription drug sales.
FiercePharma
AstraZeneca has dumped billions into Brilinta R&D, but will it ever pay off?
With an estimated $5.4 billion in sunk costs in Brilinta, AstraZeneca will likely never turn a profit on the blood thinner with generics expected to hit the market in…
Nikkei Asian Review
Daiichi Sankyo harnesses 'old' R&D to strike cancer drug gold
Research firm EvaluatePharma sees global sales of Enhertu in the $2 billion range in 2024, and Fumiyoshi Sakai of Credit Suisse Securities (Japan) predicts peak annual…
PMLive
Sanofi completes acquisition of immuno-oncology specialist Synthorx
Analysts don’t see Libtayo making a big impression in the field, however – Evaluate Pharma forecasts the drug reaching revenues of just $600m by 2024, far behind Merck…
The Pharma Letter
PharmaMar and Jazz Pharma lurbinectedin deal now effective
Zepsyre carries 2024 sales forecasts of $163 million, implying an NPV of $600 million, according to EvaluatePharma
BioSpace
Is Alzheimer's Type 3 Diabetes? Novo Nordisk is Willing to Find Out
Novo Nordisk shares recently popped, and Evaluate Pharma speculates that this was related to the company’s participation in the trial after the Danish newspaper Børsen…
The Pharma Letter
Look back at pharma news in the week to January 17, 2020
The sell-side expects tafasitamab to generate 2024 revenue of $661 million, according to EvaluatePharma consensus.
PMLive
Novo Nordisk gets MACE prevention claim for Ozempic in US
EvaluatePharma has previously predicted that Ozempic could become a $2.2bn product by 2022, but other analysts think it could go even higher, perhaps reaching $3bn plus…
National Law Review
Day 2 Notes at the 2020 J.P. Morgan Healthcare Conference
By 2024, the cost of gene therapies is expected to reach more than $16 billion in the United States, according to EvaluatePharma, which is both good news and bad news…
Wall Street Journal
Bristol’s Merger With Celgene Is Already Paying Dividends, CEO Says
Bristol-Myers Squibb Co., fresh off completing one of the largest drug-industry mergers ever, is counting on the acquisition to pay off quickly with new products and…
